# Outlook (OTLK) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/OTLK
## Company Profile
- Ticker: OTLK
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Ophthalmology
## Stock Data
- Close: 0.649 USD
- Market cap: 120890480.0184 USD
- Last updated: 2026-09-03
## Business Overview
### Ophthalmic Bevacizumab Company
Outlook Therapeutics develops and commercializes LYTENAVA, a bevacizumab formulation manufactured specifically for intravitreal administration in retinal diseases. The company is building a focused ophthalmology franchise around an approved alternative to repackaged bevacizumab originally produced for oncology use.
### LYTENAVA for Wet AMD
LYTENAVA, or bevacizumab-vikg in the United States and bevacizumab gamma in Europe, is a VEGF inhibitor approved for neovascular age-related macular degeneration. By binding VEGF-A, it is intended to suppress abnormal blood-vessel growth and vascular leakage that contribute to progressive vision loss.
### US Commercial Franchise
LYTENAVA is the first and only FDA-approved ophthalmic formulation of bevacizumab for wet AMD. Outlook is establishing US market access, reimbursement, supply, medical-affairs, patient-support, and retina-specialist commercial capabilities ahead of product availability.
### International Commercialization
LYTENAVA is also authorized in the European Union and United Kingdom and has been launched in Germany, Austria, and the UK. Outlook is pursuing additional country launches directly and through regional distribution partners.
## Why The Stock Is Moving

As of Sep 3, 2026, OTLK closed up 3.62% at $0.6490. No new same-company headline was identified in the current news window.

## Future Catalysts

- Commercial launch of LYTENAVA in the United States before the end of 2026.
- Commercial launch of LYTENAVA in the Netherlands later in 2026.
- Potential Swiss approval and partner-led commercial launch of LYTENAVA in 2027.

## Drug Assets

- ONS-5010

## Recent News
- 2026-08-27 20:05 EST — [Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™](https://biopharmsignal.com/news/OTLK/outlook-therapeutics-appoints-kevin-lundquist-as-chief-financial-officer-as-it-p-bcce914f) — Source: Outlook
- 2026-08-27 13:01 EST — [Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference](https://biopharmsignal.com/news/OTLK/outlook-therapeutics-ceo-bob-jahr-participates-in-the-virtual-investor-why-now-o-eb0c7a49) — Source: Outlook
- 2026-08-14 11:15 EST — [Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™](https://biopharmsignal.com/news/OTLK/outlook-therapeutics-reports-third-quarter-fiscal-year-2026-financial-results-an-fff0fa0f) — Source: Outlook
- 2026-08-13 01:45 EST — [Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants](https://biopharmsignal.com/news/OTLK/outlook-therapeutics-announces-pricing-of-55-0-million-public-offering-of-common-611e864e) — Source: Outlook
- 2026-08-12 20:01 EST — [Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants](https://biopharmsignal.com/news/OTLK/outlook-therapeutics-announces-proposed-public-offering-of-common-stock-and-warr-552e1f7d) — Source: Outlook